From Seekingalpha · Mike Zaccardi, CFA, CMT · · 1m
Bristol-Myers Squibb Stock: Growth Opportunity
Bristol-Myers Squibb's strong Q2 earnings and dividend offer a pullback opportunity.
In brief
Bristol-Myers Squibb's strong Q2 earnings and dividend offer a pullback opportunity. Bristol-Myers Squibb's Q2 earnings triple-play with strong growth and dividend yield presents a buying opportunity despite patent cliffs. Originally reported by Seekingalpha.
Q2 Earnings Triple-Play
Bristol-Myers Squibb delivered strong Q2 earnings with raised FY 2026 sales guidance and robust growth in both legacy and new products.
Dividend Yield and Valuation
Bristol-Myers Squibb is reiterated as a buy with an attractive 4.23% dividend yield and strong valuation metrics.
Patent Cliffs and EPS Decline
Despite looming patent cliffs and projected EPS declines post-2026, Bristol-Myers Squibb benefits from high free cash flow and recent bullish EPS revisions.
Technical Support and Resistance
Technical support at the 200-day moving average and strong free cash flow suggest resilience, though resistance at $63 and pipeline execution remain key watchpoints.
Pullback Opportunity
Bristol-Myers Squibb's stock pullback presents an opportunity for investors given strong fundamentals and recent earnings performance.
The headline
Bristol-Myers Squibb's Q2 earnings triple-play with strong growth and dividend yield presents a buying opportunity despite patent cliffs.
